McKelligon Brian 4
4 · Akoya Biosciences, Inc. · Filed Jun 12, 2024
Insider Transaction Report
Form 4
McKelligon Brian
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2024-06-11$2.08/sh−7,500$15,630→ 224,733 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2024-06-11−7,500→ 275,629 totalExercise: $0.30Exp: 2027-11-09→ Common Stock (7,500 underlying) - Exercise/Conversion
Common Stock
2024-06-11$0.30/sh+7,500$2,273→ 232,233 total
Footnotes (3)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Brian M. McKelligon dated August 16, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.04 to $2.16, inclusive. The reporting person undertakes to provide to Akoya Biosciences, Inc., any security holder of Akoya Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
- [F3]The option, representing a right to purchase a total of 353,129 shares, became exercisable as follows: one-fourth of the shares vested on July 14, 2018 with the remaining shares vesting in 36 equal monthly installments beginning on August 14, 2018, subject to reporting person's continuous employment.